-
11.发明授权公开(公告)号：US11267888B2
公开(公告)日：2022-03-08
申请号：US16842885
申请日：2020-04-08
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Xavier Valencia , John P. Throup , Steven G. Nadler , Suzanne J. Suchard , Dominique Duchesne , Xiaoni Liu , Rong Shi , Diane E. Shevell , Jenny H. Xie , Marek Honczarenko
IPC: A61K39/395 , C07K16/28 , A61K47/60 , A61K45/06 , A61K39/00
Abstract: Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.
-
公开(公告)号：US20210047414A1
公开(公告)日：2021-02-18
申请号：US17086565
申请日：2020-11-02
Applicant: Bristol-Myers Squibb Company , Domantis Limited
Inventor： Murray McKinnon , Steven G. Nadler , Suzanne J. Suchard , Brendan Classon , Steve Holmes , Olga Ignatovich , Christopher Plummer , Steve Grant
IPC: C07K16/28 , A61K39/395 , A61K45/06
Abstract: Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.
-
公开(公告)号：US09228018B2
公开(公告)日：2016-01-05
申请号：US14510474
申请日：2014-10-09
Applicant: Bristol-Myers Squibb Company , Domantis Limited
Inventor： Steven G. Nadler , James K. Tamura , Laura Price , Robert P. Rehfuss , Suzanne J. Suchard , Anish Suri , James William Bryson , Aaron Yamniuk , Steven Grant , Olga Ignatovich , Philip Drew
CPC classification number: C07K16/2878 , A61K38/00 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/545 , C07K16/18 , C07K16/283 , C07K16/2833 , C07K16/2875 , C07K16/2896 , C07K16/46 , C07K16/468 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/52 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/00 , C07K2319/30
Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
Abstract translation: 提供了特异性结合人CD40L的抗体多肽。 抗体多肽不激活血小板。 抗体多肽可用于治疗涉及CD40L活化的疾病，例如移植物相关疾病和自身免疫性疾病。 抗体多肽可以是包含单个VH或VK结构域的结构域抗体（dAb）。 抗体多肽的半衰期可以通过将抗体多肽修饰为也可以结合人血清白蛋白（HSA）或另一抗原的双特异性试剂来增加。
-
14.发明授权公开(公告)号：US11912769B2
公开(公告)日：2024-02-27
申请号：US17584207
申请日：2022-01-25
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Xavier Valencia , John P. Throup , Steven G. Nadler , Suzanne J. Suchard , Dominique Duchesne , Xiaoni Liu , Rong Shi , Diane E. Shevell , Jenny H. Xie , Marek Honczarenko
IPC: A61K39/395 , C07K16/28 , A61K47/60 , A61K45/06 , A61K39/00
CPC classification number: C07K16/2818 , A61K39/3955 , A61K45/06 , A61K47/60 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/24 , C07K2317/565 , C07K2317/569 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/31
Abstract: Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.
-
Patent Agency Ranking
15.发明申请公开(公告)号：US20220144951A1
公开(公告)日：2022-05-12
申请号：US17584207
申请日：2022-01-25
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Xavier Valencia , John P. Throup , Steven G. Nadler , Suzanne J. Suchard , Dominique Duchesne , Xiaoni Liu , Rong Shi , Diane E. Shevell , Jenny H. Xie , Marek Honczarenko
IPC: C07K16/28 , A61K47/60 , A61K39/395 , A61K45/06
Abstract: Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.
-
公开(公告)号：US11180567B2
公开(公告)日：2021-11-23
申请号：US16218077
申请日：2018-12-12
Applicant: Bristol-Myers Squibb Company , Domantis Limited
Inventor： Steven G. Nadler , James K. Tamura , Laura Price , Robert P. Rehfuss , Suzanne J. Suchard , Anish Suri , James William Bryson , Aaron Yamniuk , Steven Grant , Olga Ignatovich , Philip Drew
Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
-
17.发明授权公开(公告)号：US10196451B2
公开(公告)日：2019-02-05
申请号：US15668305
申请日：2017-08-03
Applicant: Bristol-Myers Squibb Company , Domantis Limited
Inventor： Steven G. Nadler , James K. Tamura , Laura Price , Robert P. Rehfuss , Suzanne J. Suchard , Anish Suri , James William Bryson , Aaron Yamniuk , Steven Grant , Olga Ignatovich , Philip Drew
Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
-
公开(公告)号：US09765150B2
公开(公告)日：2017-09-19
申请号：US14950949
申请日：2015-11-24
Applicant: Bristol-Myers Squibb Company , Domantis Limited
Inventor： Steven G. Nadler , James K. Tamura , Laura Price , Robert P. Rehfuss , Suzanne J. Suchard , Anish Suri , James William Bryson , Aaron Yamniuk , Steven Grant , Olga Ignatovich , Philip Drew
CPC classification number: C07K16/2878 , A61K38/00 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/545 , C07K16/18 , C07K16/283 , C07K16/2833 , C07K16/2875 , C07K16/2896 , C07K16/46 , C07K16/468 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/52 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/00 , C07K2319/30
Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
-
公开(公告)号：US08895010B2
公开(公告)日：2014-11-25
申请号：US13650493
申请日：2012-10-12
Applicant: Bristol-Myers Squibb Company , Domantis Limited
Inventor： Steven G. Nadler , James K. Tamura , Laura Price , Robert P. Rehfuss , Suzanne J. Suchard , Anish Suri , James William Bryson , Aaron Yamniuk , Steven Grant , Olga Ignatovich , Philip Drew
CPC classification number: C07K16/2878 , A61K38/00 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/545 , C07K16/18 , C07K16/283 , C07K16/2833 , C07K16/2875 , C07K16/2896 , C07K16/46 , C07K16/468 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/52 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/00 , C07K2319/30
Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
Abstract translation: 提供了特异性结合人CD40L的抗体多肽。 抗体多肽不激活血小板。 抗体多肽可用于治疗涉及CD40L活化的疾病，例如移植物相关疾病和自身免疫性疾病。 抗体多肽可以是包含单个VH或VK结构域的结构域抗体（dAb）。 抗体多肽的半衰期可以通过将抗体多肽修饰为也可以结合人血清白蛋白（HSA）或另一抗原的双特异性试剂来增加。
-
-
-
-
-
-
-
-
Search Results
19
records
(took 0.034 seconds)
